Bicocca Open Archive

Logo unimib boa
MOLOGNI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.376
EU - Europa 4.597
AS - Asia 2.063
SA - Sud America 104
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 9
Totale 15.185
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.245
IT - Italia 1.290
DE - Germania 802
SG - Singapore 751
CN - Cina 689
IE - Irlanda 638
SE - Svezia 542
RU - Federazione Russa 367
HK - Hong Kong 307
UA - Ucraina 271
GB - Regno Unito 204
CA - Canada 127
FI - Finlandia 104
FR - Francia 93
BR - Brasile 87
ID - Indonesia 85
IN - India 77
PL - Polonia 73
BE - Belgio 62
VN - Vietnam 47
TR - Turchia 45
DK - Danimarca 36
NL - Olanda 36
AT - Austria 17
IR - Iran 15
EU - Europa 14
ES - Italia 13
JP - Giappone 10
KR - Corea 10
AU - Australia 9
LT - Lituania 8
PE - Perù 8
CZ - Repubblica Ceca 6
EG - Egitto 5
RO - Romania 5
BG - Bulgaria 4
CL - Cile 4
MK - Macedonia 4
NO - Norvegia 4
AR - Argentina 3
CH - Svizzera 3
KE - Kenya 3
MA - Marocco 3
MX - Messico 3
MY - Malesia 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
AZ - Azerbaigian 2
BD - Bangladesh 2
BY - Bielorussia 2
EC - Ecuador 2
GR - Grecia 2
JO - Giordania 2
KZ - Kazakistan 2
MU - Mauritius 2
PT - Portogallo 2
RS - Serbia 2
SC - Seychelles 2
TH - Thailandia 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
DZ - Algeria 1
EE - Estonia 1
IQ - Iraq 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
NG - Nigeria 1
NP - Nepal 1
PK - Pakistan 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
YE - Yemen 1
Totale 15.185
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.939
Woodbridge 726
Fairfield 689
Dublin 628
Chandler 602
Frankfurt am Main 594
Singapore 572
Milan 512
Wilmington 444
Houston 410
Ashburn 382
Hong Kong 306
Jacksonville 267
Seattle 253
Cambridge 247
Dearborn 247
New York 238
Santa Clara 198
Princeton 172
Nanjing 124
Shanghai 121
Jakarta 85
Altamura 83
Lawrence 79
Beijing 71
Lodz 70
Brussels 58
Helsinki 53
San Diego 47
Lachine 44
Boardman 41
Fremont 38
Guangzhou 37
Lissone 36
Shenyang 34
Los Angeles 33
Munich 32
Nanchang 32
Andover 31
Toronto 31
Rome 30
Ottawa 29
Romola 29
Göttingen 27
Nuremberg 24
Jinan 22
Carate Brianza 21
Falls Church 21
Jiaxing 21
Hebei 20
Kunming 20
London 20
Monza 20
Mountain View 19
Norwalk 19
Chicago 18
Kocaeli 17
Pune 17
Dong Ket 16
Edmonton 16
Hangzhou 16
Tianjin 16
Desio 15
Redmond 13
Turin 13
Changsha 12
Sesto San Giovanni 12
Como 11
Kiev 11
Taizhou 11
Bari 10
Cesano Maderno 10
Genoa 10
São Paulo 10
Zhengzhou 10
Bonndorf 9
Cinisello Balsamo 9
Fürstenwalde 9
Paris 9
Hefei 8
Washington 8
Changchun 7
Daejeon 7
Huizen 7
Lima 7
Mumbai 7
Riva del Garda 7
Vienna 7
Boston 6
Detroit 6
Duncan 6
Kilburn 6
Lanzhou 6
Lleida 6
Meda 6
Ningbo 6
Peschiera Borromeo 6
Phoenix 6
Corsico 5
Delhi 5
Totale 11.383
Salva come PNG Salva come JPEG
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 361
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 325
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 296
Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer 282
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 275
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 268
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 266
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 261
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 249
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 228
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 227
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 220
Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer 213
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 210
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 206
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 204
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 204
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 203
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 200
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 197
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 197
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 195
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 195
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 194
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 193
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 193
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 192
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 189
Inhibition of RET tyrosine kinase by SU5416 189
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 184
Expression, purification, and inhibition of human RET tyrosine kinase 182
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 180
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 179
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 178
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 176
Dissection of the RET/ß-catenin interaction in the TPC1 thyroid cancer cell line 174
We shall overcome (drug resistance) some day 172
Efficacy of a cancer vaccine against ALK-rearranged lung tumors 171
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 169
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 167
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 167
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer 165
Dual kinase targeting in leukemia 165
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 162
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 162
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma 159
Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications 157
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells 153
Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3- thienyl)nicotinonitrile scaffold 152
Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism 150
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 147
Current and future treatment of anaplastic lymphoma kinase-rearranged cancer 145
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 141
Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting 140
Novel targeted therapeutics for MEN2 140
Unique substrate specificity of Anaplastic Lymphoma Kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity 139
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 135
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 134
Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl 133
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 131
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma 127
Anaplastic Lymphoma kinase assay, reagents and composition thereof 122
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 122
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 118
New developments in the treatment of ALK-driven malignancies 118
Targeted deletion of the muscular dystrophy gene myotilin does not perturb muscle structure or function in mice 118
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients 117
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 116
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 113
RET kinase inhibitors: a review of recent patents (2012–2015) 113
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 113
β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: Implications for a double-targeted therapy 109
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 108
The novel PIM1 inhibitor NMS-P645 reverses PIM1-Dependent effects on TMPRSS2/ERG positive Prostate cancer cells and shows anti-proliferative activity in combination with PI3K inhibition 102
Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells 102
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma 102
Characterization of the transcriptional landscape of atypical Chronic Myeloid Leukemia at single-cell resolution 101
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 100
Characterization of mouse myotilin and its promoter 100
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 97
Expanding the portfolio of anti-ALK weapons 97
Role of TMPRSS2/ERG in cellular transformation 96
Targeting drug resistance mutations: Discovery of EUD-GK-91 chemical series 94
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 91
Discovery of wtRET and V804MRET Inhibitors: From Hit to Lead 91
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 90
SETBP1 accumulation induces P53 inhibition and genotoxic stress in neural progenitors underlying neurodegeneration in Schinzel-Giedion syndrome 90
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 89
Balanced SET levels favor the correct enhancer repertoire during cell fate acquisition 86
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 86
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 84
Synergistic activity of dasatinib in combination with β-catenin blockade in colorectal cancer cells 82
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 82
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo 79
Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering 77
Development of RET kinase inhibitors for targeted cancer therapy 77
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 75
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 69
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 67
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma 61
Totale 15.422
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.334
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.334
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020836 0 0 0 0 0 0 0 208 237 171 159 61
2020/20212.141 93 107 204 252 168 208 179 214 187 204 151 174
2021/20221.316 112 154 136 70 54 102 80 72 62 119 147 208
2022/20232.642 289 734 209 237 176 353 28 138 180 134 85 79
2023/20242.204 113 87 98 113 255 562 400 68 177 57 55 219
2024/20252.402 275 476 319 278 440 200 369 45 0 0 0 0
Totale 15.854